Compounds > racemetirosine
Page last updated: 2024-10-26

racemetirosine and Parkinson Disease

racemetirosine has been researched along with Parkinson Disease in 13 studies

alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research Excerpts

ExcerptRelevanceReference
"A crucial event in the pathogenesis of Parkinson's disease is the death of dopaminergic neurons of the nigrostriatal system, which are responsible for the regulation of motor function."1.46Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease. ( Khakimova, GR; Kozina, EA; Kucheryanu, VG; Ugrumov, MV, 2017)
"Reserpine was injected in a dose of 10 mg/kg alone or with alpha-methyl-p-tyrosine (250 mg/kg) 1, 4 and 27."1.29Does reserpine induce parkinsonian rigidity? ( Lorenc-Koci, E; Ossowska, K; Wardas, J; Wolfarth, S, 1995)
"Pretreatment with haloperidol and sulpiride blocked the effects induced by ciladopa."1.27Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug. ( Fields, JZ; Gordon, JH; Koller, WC; Perlow, MJ, 1986)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19905 (38.46)18.7374
1990's2 (15.38)18.2507
2000's4 (30.77)29.6817
2010's2 (15.38)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Khakimova, GR1
Kozina, EA1
Kucheryanu, VG1
Ugrumov, MV1
Fuentes, R1
Petersson, P1
Siesser, WB1
Caron, MG1
Nicolelis, MA1
Lima, MM1
Andersen, ML1
Reksidler, AB1
Ferraz, AC1
Vital, MA1
Tufik, S1
Yoshimoto, Y1
Nakaso, K1
Nakashima, K1
Zhou, Z1
Kerk, S1
Meng Lim, T1
Gervas, JJ1
Muradás, V1
Bazán, E1
Aguado, EG1
de Yébenes, JG2
Diamond, BI1
Pasinetti, G1
Hitri, A1
Borison, RL1
Fahn, S2
Lorenc-Koci, E1
Ossowska, K1
Wardas, J1
Wolfarth, S1
Drukarch, B1
Jongenelen, CA1
Schepens, E1
Langeveld, CH1
Stoof, JC1
Pendleton, RG1
Parvez, F1
Sayed, M1
Hillman, R1
Jackson-Lewis, V1
Jorge, P1
Mena, MA1
Reiriz, J1
Koller, WC1
Fields, JZ1
Gordon, JH1
Perlow, MJ1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease[NCT03079310]15 participants (Anticipated)Interventional2016-02-29Recruiting
Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.[NCT03526991]10 participants (Anticipated)Interventional2021-08-01Recruiting
STIMO-PARKINSON: Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease[NCT04956770]2 participants (Actual)Interventional2021-06-14Active, not recruiting
Effects of Repetitive Trans Spinal Magnetic Stimulation Associated With Treadmill Gait Training on Gait Disorders in Patients With Parkinson's Disease[NCT05938673]76 participants (Anticipated)Interventional2023-11-30Recruiting
Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease; a Randomized, Crossover, Double Blinded, Placebo-Controlled Study[NCT05148468]12 participants (Anticipated)Interventional2021-11-30Active, not recruiting
Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease[NCT02388204]20 participants (Anticipated)Interventional2014-06-30Recruiting
Efficacy of Repetitive Trans-spinal Magnetic Stimulation on Gait Abnormalities in Parkinson's Disease Patients: A Double-blinded Randomized Controlled Trial[NCT05271513]38 participants (Actual)Interventional2023-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

13 other studies available for racemetirosine and Parkinson Disease

ArticleYear
Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Molecular neurobiology, 2017, Volume: 54, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Methyltyrosine; Animals; Catecholamines; Early D

2017
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
    Science (New York, N.Y.), 2009, Mar-20, Volume: 323, Issue:5921

    Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami

2009
Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion.
    CNS & neurological disorders drug targets, 2012, Jun-01, Volume: 11, Issue:4

    Topics: alpha-Methyltyrosine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Down-Regulati

2012
L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells.
    FEBS letters, 2005, Feb-14, Volume: 579, Issue:5

    Topics: alpha-Methyltyrosine; Animals; Cathepsin B; Cell Survival; Dopamine; Leupeptins; Levodopa; Parkinson

2005
Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132.
    Free radical research, 2008, Volume: 42, Issue:5

    Topics: alpha-Methyltyrosine; Animals; Cell Survival; Cysteine Proteinase Inhibitors; Dopamine; Leupeptins;

2008
Effects of 3-OM-dopa on monoamine metabolism in rat brain.
    Neurology, 1983, Volume: 33, Issue:3

    Topics: alpha-Methyltyrosine; Animals; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Dopamine; Levodopa;

1983
Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's disease.
    Advances in neurology, 1984, Volume: 40

    Topics: alpha-Methyltyrosine; Animals; Brain; Cholecystokinin; Dopamine; Drug Interactions; Extrapyramidal T

1984
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
    Advances in neurology, 1983, Volume: 37

    Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combinat

1983
Does reserpine induce parkinsonian rigidity?
    Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 9, Issue:2-3

    Topics: Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Electromyography; Enzyme Inhibitors; Hi

1995
Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1996, Oct-01, Volume: 16, Issue:19

    Topics: alpha-Methyltyrosine; Animals; Buthionine Sulfoximine; Cytoplasmic Granules; Dopamine; Glutathione;

1996
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 300, Issue:1

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; alpha-Synuclein; A

2002
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    Journal of neural transmission. Supplementum, 1988, Volume: 27

    Topics: alpha-Methyltyrosine; Animals; Brain Diseases; Catheterization; Cerebral Ventricles; Disease Models,

1988
Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug.
    Neuropharmacology, 1986, Volume: 25, Issue:9

    Topics: alpha-Methyltyrosine; Animals; Apomorphine; Body Temperature; Dogs; Dose-Response Relationship, Drug

1986